# CARMEN-LC05 (NCT04524689)

> Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

No report yet. It can be ordered.

- Drugs tested: tusamitamab ravtansine plus pembrolizumab; tusamitamab ravtansine plus pembrolizumab plus platinum-based chemotherapy; tusamitamab ravtansine plus pembrolizumab plus platinum-based chemotherapy plus pemetrexed
- Indication: CEACAM5-positive advanced/metastatic non-squamous non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04524689
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Sanofi
- Conditions: Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Interventions: SAR408701 (Tusamitamab ravtansine); Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed
- Enrollment: 57
- Primary outcome: All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs)
- Primary outcome: Doublet Cohort: Objective Response Rate (ORR)
- Primary outcome: Quadruplet Cohort: Objective Response Rate

## Indexed commentary on CARMEN-LC05 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 1
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=carmen-lc05-nct04524689